Compare KOPN & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOPN | ENTX |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.9M | 142.0M |
| IPO Year | 1992 | 2018 |
| Metric | KOPN | ENTX |
|---|---|---|
| Price | $2.40 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.25 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 3.3M | 85.0K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,602,295.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.02 | ★ 25.25 |
| 52 Week Low | $0.71 | $1.50 |
| 52 Week High | $4.16 | $3.22 |
| Indicator | KOPN | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 27.62 |
| Support Level | $2.28 | $2.07 |
| Resistance Level | $2.65 | $2.22 |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 22.22 | 0.00 |
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.